192 related articles for article (PubMed ID: 24213121)
1. Peptide Based Vaccine Approaches for Cancer-A Novel Approach Using a WT-1 Synthetic Long Peptide and the IRX-2 Immunomodulatory Regimen.
Naylor PH; Egan JE; Berinstein NL
Cancers (Basel); 2011 Oct; 3(4):3991-4009. PubMed ID: 24213121
[TBL] [Abstract][Full Text] [Related]
2. IRX-2 increases the T cell-specific immune response to protein/peptide vaccines.
Naylor PH; Hernandez KE; Nixon AE; Brandwein HJ; Haas GP; Wang CY; Hadden JW
Vaccine; 2010 Oct; 28(43):7054-62. PubMed ID: 20708999
[TBL] [Abstract][Full Text] [Related]
3. Rational Design of T-Cell- and B-Cell-Based Therapeutic Cancer Vaccines.
Li WH; Su JY; Li YM
Acc Chem Res; 2022 Sep; 55(18):2660-2671. PubMed ID: 36048514
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
[TBL] [Abstract][Full Text] [Related]
5. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.
Cluff CW
Adv Exp Med Biol; 2010; 667():111-23. PubMed ID: 20665204
[TBL] [Abstract][Full Text] [Related]
6. Optimal long peptide for flagellin-adjuvanted HPV E7 cancer vaccine to enhance tumor suppression in combination with anti-PD-1.
Lee HH; Hong SH; Rhee JH; Lee SE
Transl Cancer Res; 2022 Jun; 11(6):1595-1602. PubMed ID: 35836530
[TBL] [Abstract][Full Text] [Related]
7. Rational Design of Antigen Incorporation Into Subunit Vaccine Biomaterials Can Enhance Antigen-Specific Immune Responses.
Tsoras AN; Wong KM; Paravastu AK; Champion JA
Front Immunol; 2020; 11():1547. PubMed ID: 32849524
[TBL] [Abstract][Full Text] [Related]
8. Sulfated Lactosyl Archaeol Archaeosomes Synergize with Poly(I:C) to Enhance the Immunogenicity and Efficacy of a Synthetic Long Peptide-Based Vaccine in a Melanoma Tumor Model.
Akache B; Agbayani G; Stark FC; Jia Y; Dudani R; Harrison BA; Deschatelets L; Chandan V; Lam E; Hemraz UD; Régnier S; Krishnan L; McCluskie MJ
Pharmaceutics; 2021 Feb; 13(2):. PubMed ID: 33673382
[TBL] [Abstract][Full Text] [Related]
9. Preclinical studies with IRX-2 and thymosin alpha1 in combination therapy.
Naylor PH; Hadden JW
Ann N Y Acad Sci; 2010 Apr; 1194():162-8. PubMed ID: 20536465
[TBL] [Abstract][Full Text] [Related]
10. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
Jasani B; Navabi H; Adams M
Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of two different adjuvants with immunogenic uroplakin 3A-derived peptide for their ability to evoke an immune response in mice.
Izgi K; Iskender B; Sakalar C; Arslanhan A; Saraymen B; Canatan H
Eur Cytokine Netw; 2015; 26(2):46-56. PubMed ID: 26553588
[TBL] [Abstract][Full Text] [Related]
12. Nanoscale Metal-Organic Frameworks for Cancer Immunotherapy.
Ni K; Luo T; Nash GT; Lin W
Acc Chem Res; 2020 Sep; 53(9):1739-1748. PubMed ID: 32808760
[TBL] [Abstract][Full Text] [Related]
13. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
Amanpour S
Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
[TBL] [Abstract][Full Text] [Related]
14. Adjuvants in perspective.
Vogel FR
Dev Biol Stand; 1998; 92():241-8. PubMed ID: 9554280
[TBL] [Abstract][Full Text] [Related]
15. Immunodeficiency and cancer: prospects for correction.
Hadden JW
Int Immunopharmacol; 2003 Aug; 3(8):1061-71. PubMed ID: 12860163
[TBL] [Abstract][Full Text] [Related]
16. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
[TBL] [Abstract][Full Text] [Related]
17. Vaccine Trials for the Clinician: Prospects for Tumor Antigens.
Osanto S
Oncologist; 1997; 2(5):284-299. PubMed ID: 10388061
[TBL] [Abstract][Full Text] [Related]
18. Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles.
Yan H; Lin G; Liu Z; Gu F; Zhang Y
Acta Biomater; 2023 Apr; 161():213-225. PubMed ID: 36858163
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the immune response in patients with cancer of the oral cavity after neoadjuvant immunotherapy with the IRX-2 regimen.
Liu S; Bellile E; Nguyen A; Zarins K; D'Silva N; Rozek L; Wolf GT; Sartor MA;
Oral Oncol; 2021 Dec; 123():105587. PubMed ID: 34717154
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of HIV-1 Env-Specific CD8 T Cell Responses Using Interferon-Stimulated Gene 15 as an Immune Adjuvant.
Gómez CE; Perdiguero B; Falqui M; Marín MQ; Bécares M; Sorzano CÓS; García-Arriaza J; Esteban M; Guerra S
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
